Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents

Abstract

We studied the overview of drug discovery and development to understand the recent trends and potential success factors of interorganizational collaboration by reviewing 1204 transactions performed until 2019 for 107 anticancer drugs approved by the US Food and Drug Administration (FDA) from 1999 to 2018. Immune checkpoint blockade was found to be a significantly active area in interorganizational transactions, especially the number of alliances, compared with other mechanisms of action of small molecules and biologics for cancer treatment. Furthermore, the analysis of pembrolizumab and nivolumab showed that the number of approved indications for these two drugs has been rapidly expanding since their first approval in 2014. Examination of the acquisitions and alliances regarding pembrolizumab and nivolumab showed that many combination partners were developed by US-based biotechnology or start-up companies, the majority of which were biologics. These findings suggest that immune checkpoint blockade is a paradigm for cancer treatment, resulting in huge product sales and continuous indication expansion. Additionally, interorganizational collaboration, especially trial collaboration, is a strategic approach for the development of immune checkpoint blockade agents. The translation of these empirical practices to new drug candidates is expected for the research and development of innovative drugs in the future.

Open Innovation: A Research Framework and Case Study of Huawei

“…SMEs will be more adaptable than large companies, benefiting from their small scale; (b) The dynamic integration of internal and external innovative resources: The effective integration is particularly important for the innovation and development of enterprises. In an open environment, efficient knowledge flow and cooperation networks (Djurian et al, 2021) are important factors that affect the integration of enterprise innovation resources and lay a solid foundation for research and development of core products; (c) The applications in different industries: To explore the characteristics of OI implemented by enterprises in different industries, scholars have launched a series of personalized studies. For example, Saguy and Sirotinskaya (2014) pointed that the food industry faces numerous complex challenges, especially SMEs in this industry.…”

Personalized and Precision Medicine 2022

“…The study presents candidate systems’ biomarkers that may be valuable for improving personalized treatment strategies for various cancers. The review by K. Kodama et al [ 9 ] proposes a large overview of the discovery and development of 107 anticancer drugs, in connection with interorganizational collaboration, from 1998 to 2018. It is shown that immune checkpoint blockade agents are a significantly active area in interorganizational transactions, suggesting that such types of agents are a paradigm for cancer treatment, resulting in huge product sales and continuous indication expansion.…”